Strategic Advisory Group of Experts on Immunization (SAGE) - October 2015

20 – 22 October 2015

Related

Background documents and presentations

SAGE Yellow Book - October 2015

 

Session: Report from IVB director

Session: Ebola vaccine

Background documents

Report of the SAGE Working Group on Ebola Vaccines and Vaccination with provisional recommendations for vaccination: Section A: Introduction, epidemiology and risk factors

Report of the SAGE Working Group on Ebola Vaccines and Vaccination with provisional recommendations for vaccination: Section B: Vaccines and vaccination

Report of the SAGE Working Group on Ebola Vaccines and Vaccination with provisional recommendations for vaccination: Section C: Conclusions and recommendations

The ring vaccination trial: a novel cluster randomized controlled trial design to evaluate vaccine efficacy and effectiveness during outbreaks, with special reference to Ebola

Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial

Presentations

Epidemiology and risk factors for EVD - B. Aylward and C. Dye

Status of vaccine development , preliminary results from clinical trials, modelled projections of impact and deployment plans - V. Moorthy, A M. Henao Restrepo and M P Preziosi

Projections of impact of vaccination under different epidemiological scenarios - J Edmunds

Blueprint for R&D during emergencies - M P. Kieny

Conclusions and draft recommendations from the WG - H. Rees

Show less Show more

Session: report from GAVI

Session: Polio

Background documents

SAGE Polio Working Group, 6 June 2015, WG conference call notes

SAGE Polio Working Group, 7-8 September 2015, WG meeting summary

Evidence to recommendation Table: SAGE polio WG

World Health Assembly Resolution (2015) WHA68.3: Poliomyelitis

Overview on implementation plan for type 2 containment

Plans for containment of poliovirus following type-specific polio eradication worldwide, 2015. WER 7 August 2015

World Health Organization Guidelines for containment of poliovirus following type-specific polio eradication – Worldwide, 2015. MMWR, 28 August 2015

Framework for monitoring tOPV withdrawal Executive Summary

Presentations

Objective of the session; overview of Global Polio Eradication Initiative - H. Jafari

Updates on preparation for OPV2 withdrawal - M. Zaffran

Report from SAGE Working Group -Y. AL Mazrou

Updates on legacy planning - S. Cochi, P. Rutter

Show less Show more

Session: Measles and rubella

Background documents

Measles re-vaccination of HIV-infected children on anti-retroviral therapy - W. Moss

GVAP measles secretariat report

GVAP rubella secretariat report

Proceedings and draft recommendations from the fifth meeting of the SAGE Working group on Measles and Rubella, 3-4 September 2015, Geneva

Systematic review of literature on use of MCV at <9 months

Presentation on Immunological tolerance

Presentation on decay of maternal antibodies for measles

Presentation on decay of maternal antibodies for rubella

Presentation on Use of mumps vaccine at <9 months

Evidence supporting measles re-vaccination for HIV-infected children receiving highly active anti-retroviral therapy

Presentations

Update on global measles and rubella control and regional elimination - P. Strebel

Refinements to the vaccination strategies for measles and rubella control and elimination - P. Figueroa

Show less Show more

Session: Reports from other Advisory Committees on Immunization

Background documents

Report of the Expert Committee on Biological Standardization (ECBS) - E. Griffiths

Global Advisory Committee on Vaccine Safety, 10–11 June 2015. WER, 17 July 2015

Immunization and Vaccine-related Implementation Research Advisory Committee (IVIR-AC): summary of conclusions and recommendations,9–11 June 2015 meeting. WER, 11 September 2015

Product Development for Vaccines Advisory Committee (PDVAC) 7-9 September. Initial Summary and PDVAC List of global pathogen-specific vaccine pipeline analyses developed for PDVAC committee

Presentations

Report of the Global Advisory Committee on Vaccine Safety (GACVS) - M. Wharton

Report of the Product Development for Vaccines Advisory Committee (PDVAC) - D. Kaslow

Report of the Immunization Practices Advisory Committee (IPAC) - C. Morgan

Report of the Immunization and vaccines related implementation research advisory committee (IVIR-AC) - G. Kang

Show less Show more

Session: Malaria vaccine - Joint session Malaria Policy Advisory Committee / SAGE

Background documents

Background paper on the RTS,S/AS01 malaria vaccine (without appendices)

Appendices - background paper on the RTS,S/AS01 malaria vaccine

WHO, prepared for JTEG: Programmatic Options for Implementation of RTS,S Malaria Vaccination Schedule

Summary of key outcomes: The public health impact and cost-effectiveness of malaria vaccine RTS,S/AS01: a systematic comparison of predictions and four mathematical models. Unpublished

Comparison of the cost effectiveness of LLINs, SMC, the RTS,S vaccine and RTS,S plus IPTi in African settings. Unpublished

Presentations

Malaria disease burden, epidemiology, status of malaria control and surveillance, and the need for new interventions - K. Marsh

Review of RTS,S clinical trial results - P. Smith

JTEG assessment and proposed recommendations - P. Smith

Show less Show more

Session: Global Vaccine Action Plan progress report

Session: Report from immunization partners

Background documents

There are no background documents for this session.

Presentations

Presentation by UNICEF - H. Deehan

Presentation by Médecins Sans Frontières (MSF) - A. Juan-Giner

Show less Show more